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Structural and functional analysis of the transcriptional regulator Rv3066
of Mycobacterium tuberculosis
Abstract
The Mmr multidrug efflux pump recognizes and actively extrudes a broad range of antimicrobial agents, and
promotes the intrinsic resistance to these antimicrobials in Mycobacterium tuberculosis . The expression of
Mmr is controlled by the TetR-like transcriptional regulator Rv3066, whose open reading frame is located
downstream of the mmr operon. To understand the structural basis of Rv3066 regulation, we have determined
the crystal structures of Rv3066, both in the absence and presence of bound ethidium, revealing an
asymmetric homodimeric two-domain molecule with an entirely helical architecture. The structures
underscore the flexibility and plasticity of the regulator essential for multidrug recognition. Comparison of
the apo-Rv3066 and Rv3066–ethidium crystal structures suggests that the conformational changes leading to
drug-mediated derepression is primarily due to a rigid body rotational motion within the dimer interface of
the regulator. The Rv3066 regulator creates a multidrug-binding pocket, which contains five aromatic residues.
The bound ethidium is found buried within the multidrug-binding site, where extensive aromatic stacking
interactions seemingly govern the binding. In vitro studies reveal that the dimeric Rv3066 regulator binds to a
14-bp palindromic inverted repeat sequence in the nanomolar range. These findings provide new insight into
the mechanisms of ligand binding and Rv3066 regulation.
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ABSTRACT
The Mmr multidrug efflux pump recognizes and
actively extrudes a broad range of antimicrobial
agents, and promotes the intrinsic resistance to
these antimicrobials inMycobacterium tuberculosis.
The expression of Mmr is controlled by the TetR-like
transcriptional regulator Rv3066, whose open
reading frame is located downstream of the mmr
operon. To understand the structural basis of
Rv3066 regulation, we have determined the crystal
structures of Rv3066, both in the absence and
presence of bound ethidium, revealing an asymmet-
ric homodimeric two-domain molecule with an
entirely helical architecture. The structures under-
score the flexibility and plasticity of the regulator
essential for multidrug recognition. Comparison of
the apo-Rv3066 and Rv3066–ethidium crystal
structures suggests that the conformational
changes leading to drug-mediated derepression is
primarily due to a rigid body rotational motion within
the dimer interface of the regulator. The Rv3066
regulator creates a multidrug-binding pocket,
which contains five aromatic residues. The bound
ethidium is found buried within the multidrug-
binding site, where extensive aromatic stacking
interactions seemingly govern the binding. In vitro
studies reveal that the dimeric Rv3066 regulator
binds to a 14-bp palindromic inverted repeat
sequence in the nanomolar range. These findings
provide new insight into the mechanisms of ligand
binding and Rv3066 regulation.
INTRODUCTION
Tuberculosis (TB) is one of the most deadly diseases and
was responsible for the death of 1.7 million people in 2009
(1) (http://www.who.int/mediacentre/factsheets/fs104/en/
index.html). This disease is caused by the bacterium
Mycobacterium tuberculosis, which infects an estimated
9 million people each year. TB is very difﬁcult to treat,
requiring at least 6 months of a combination of medica-
tions. The treatment must continue even long after the
symptoms disappear. However, M. tuberculosis has
developed resistance to commonly used anti-TB agents,
such as isoniazid and rifampicin. The development of
these drug-resistant strains is mainly due to the
mismatch between treatment and symptoms, such as the
irregular intake of drugs throughout the course of treat-
ment and inappropriate prescription of medications (2).
TB caused by multidrug-resistant (MDR) (3,4), exten-
sively drug-resistant (XDR) (2,5) and most recently
totally drug-resistant (TDR) (6) strains of M. tuberculosis
have emerged and spread globally. Based on our current
knowledge, TDR-TB is untreatable. The World Health
Organization has predicted that there will be 2 million
MDR or XDR cases worldwide by 2012. It is obvious
that the emergence of these drug-resistant TB strains has
evolved into a major threat and challenges our global
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prospects for TB control. Thus, knowledge of the molecu-
lar mechanisms underlying drug resistance in M. tubercu-
losis is essential for the development of new strategies to
combat this disease.
Recent evidence suggests that MDR strains of
M. tuberculosis are associated with constitutive or indu-
cible expression of multidrug efﬂux pumps (7). These
pumps have been classiﬁed into ﬁve different families:
the ATP-binding cassette (ABC), resistance nodulation
division (RND), multidrug and toxic compound extrusion
(MATE), major facilitator (MF) and small multidrug
resistance (SMR) families (8). It has been found that the
genome of M. tuberculosis contains genes encoding efﬂux
pumps from all these families (9,10). In addition, several
of these MDR efﬂux pumps have been identiﬁed and
characterized (9). One such pump is the Mmr (Rv3065)
multidrug efﬂux pump, which belongs to the SMR family
(11). Mmr has been shown to mediate resistance to several
toxic compounds, including acriﬂavine, ethidium bromide,
erythromycin, pyronin Y, safranin O, tetraphenylphos-
phonium and thioridazine (11,12).
Elucidating the regulatory systems of multidrug efﬂux
pumps in M. tuberculosis should allow us to understand
how this bacterium contributes to multidrug resistance
and how it adapts to environmental changes. At present,
little is known about the regulatory mechanisms modu-
lating the expression of mmr in M. tuberculosis. Here, we
report the crystal structures of the Rv3066 efﬂux regulator
both in the absence and presence of bound ethidium,
suggesting that ethidium binding triggers a rotational
motion of the regulator. This motion results in inducing
the expression of the Mmr efﬂux pump by releasing the
Rv3066 regulator from its cognate DNA at the promoter
region. The rv3066 gene is located immediately down-
stream of mmr and encodes a 202 amino acid protein
that shares sequence homology to members of the TetR
family of regulators (13,14). Our data indicate that
Rv3066 is a TetR-family regulator (15), which represses
the transcription of mmr by directly binding to the
inverted repeat (IR) of the promoter.
MATERIALS AND METHODS
Cloning of rv3066
The rv3066 ORF from genomic DNA of M. tuberculosis
strain H37Rv was ampliﬁed by polymerase chain reaction
(PCR) using the primers 50-CCATGGCAACCGCAGGC
TCCGACC-30 and 50-GGATCCTCAATGGTGATGAT
GATGATGGTCGGGGGTTCGTCCCGCAT-30 to gen-
erate a product that encodes a Rv3066 recombinant
protein with a 6xHis tag at the C-terminus. The corres-
ponding PCR product was digested with NcoI and
BamHI, extracted from the agarose gel and inserted into
pET15b as described by the manufacturer (Merck KGaA,
Darmstadt, Germany). The recombinant plasmid
(pET15brv3066) was transformed into DH5a cells and
the transformants were selected on LB agar plates con-
taining 100 mg/ml ampicillin. The presence of the correct
rv3066 sequence in the plasmid construct was veriﬁed by
DNA sequencing.
Expression and puriﬁcation of Rv3066
Brieﬂy, the full-length Rv3066 protein containing a 6xHis
tag at the C-terminus was overproduced in Escherichia coli
BL21(DE3) cells possessing pET15brv3066. Cells were
grown in 4 l of Luria Broth (LB) medium with 100 mg/ml
ampicillin at 37C. When the OD600 reached 0.5, the
culture was treated with 1mM isopropyl-b-D-thiogalacto-
pyranoside (IPTG) to induce Rv3066 expression, and cells
were harvested within 3 h. The collected bacterial cells
were suspended in 100ml ice-cold buffer containing
20mM Na-HEPES (pH 7.2) and 200mM NaCl, 10mM
MgCl2 and 0.2mg DNase I (Sigma-Aldrich). The cells
were then lysed with a French pressure cell. Cell debris
was removed by centrifugation for 45min at 4C and
20 000 rev/min. The crude lysate was ﬁltered through a
0.2mm membrane and was loaded onto a 5ml Hi-Trap
Ni2+-chelating column (GE Healthcare Biosciences,
Pittsburgh, PA, USA) pre-equilibrated with 20 mM
Na–HEPES (pH 7.2) and 200mM NaCl. To remove
unbound proteins and impurities, the column was ﬁrst
washed with six column volumes of buffer containing
50mM imidazole, 250mM NaCl and 20mM
Na–HEPES (pH 7.2). The Rv3066 protein was then
eluted with four column volumes of buffer containing
300mM imidazole, 250mM NaCl and 20mM Na–
HEPES (pH 7.2). The purity of the protein was judged
using 12.5% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis stained with Coomassie Brilliant Blue.
The puriﬁed protein was extensively dialyzed against
buffer containing 100mM imidazole, 250mM NaCl and
20mM Na–HEPES (pH 7.5) and concentrated to
20mg/ml.
For 6xHis selenomethionyl-substituted (SeMet)-Rv3066
protein expression, a 2ml LB broth overnight culture con-
taining E. coli BL21(DE3)/pET15brv3066 cells was
transferred into 40ml of LB broth containing 100 mg/ml
ampicillin and grown at 37C. When the OD600 value
reached 1.2, cells were harvested by centrifugation at
6000 rev/min for 10min, and then washed two times
with 20ml of M9 minimal salts solution. The cells were
re-suspended in 40ml of M9 media and then transferred
into a 4 l pre-warmed M9 solution containing 100 mg/ml
ampicillin. The cell culture was incubated at 37C with
shaking. When the OD600 reached 0.4, 100mg/l of
lysine, phenylalanine and threonine, 50mg/l isoleucine,
leucine and valine, and 60mg/l of L-selenomethionine
were added. The protein expression was induced with
1mM IPTG after 15min. Cells were then harvested
within 3 h after induction. The procedures for purifying
the 6xHis SeMet-Rv3066 were identical to those of the
native protein.
Crystallization of Rv3066
All crystals of the 6xHis Rv3066 regulator were ob-
tained using hanging-drop vapor diffusion. The Form
I SeMet-Rv3066 crystals were grown at room temperature
in 24-well plates with the following procedures. A 2 ml
protein solution containing 20mg/ml SeMet-Rv3066
protein in 20mM Na–HEPES (pH 7.5), 250mM
NaCl and 100mM imidazole was mixed with a 2 ml
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of reservoir solution containing 24% polyethylene glycol
(PEG) 4000, 0.1M Na-acetate (pH 5.0) and 0.2M MgCl2.
The resultant mixture was equilibrated against 500 ml of
the reservoir solution. Crystals of Form I grew to a full
size in the drops within 2 weeks. Typically, the dimensions
of the crystals were 0.2mm 0.05mm 0.05mm. Cryo-
protection was achieved by raising the PEG 4000 concen-
tration stepwise to 30% with a 3% increment in each step.
The Form II crystals of Rv3066 were prepared
using similar procedures. The reservoir solution for the
Form II crystals consists of 24% PEG 4000, 0.1M
Na–HEPES (pH 8.0) and 0.2M MgCl2. Crystals of
this form grew to a full size in the drops within 2 weeks.
The dimensions of the mature crystals were
0.1mm 0.1mm 0.1mm. Cryoprotection was achieved
by raising the PEG 4000 concentration stepwise to 30%
with a 3% increment in each step.
The Rv3066–ethidium complex crystals were prepared
by incubating the Form II crystals of apo-Rv3066 in
solution containing 24% PEG 4000, 0.1M Na–HEPES
(pH 8.0), 0.2M MgCl2 and 0.5mM ethidium bromide
for 48 h at 25C. Cryoprotection was achieved by raising
the PEG 4000 concentration stepwise to 30% with a 3%
increment in each step.
Data collection, structural determination and reﬁnement
All diffraction data were collected at 100K at beamline
24ID-E located at the Advanced Photon Source, using an
ADSC Quantum 315 CCD-based detector. Diffraction
data were processed using DENZO and scaled using
SCALEPACK (16). The crystals of Form I belong to
space group P21212 (Table 1). Based on the molecular
weight of Rv3066 (22.78 kDa), a single dimer per asym-
metric unit with a solvent content of 36.1% is expected.
Two selenium sites were identiﬁed using SHELXC and
SHELXD (17) as implemented in the HKL2MAP
package (18). Single-wavelength anomalous dispersion
(SAD) phasing using the program PHASER (19) was
employed to obtain experimental phases in addition to
phases from the structural model of the EbrR regulator
(residues 83–176) (PDB code: 3hta). The resulting phases
were then subjected to density modiﬁcation and NCS
averaging using the program PARROT (20). The phases
were of excellent quality and allowed for tracing of most
of the molecule in PHENIX AutoBuild (21), which led to
an initial model containing 72% amino acid residues and
54% of which contained side chains. The remaining part
of the model was manually constructed using the program
Table 1. Data collection, phasing and structural reﬁnement statistics
Form I Form II Rv3066–ethidium
Data Collection
Wavelength (A˚) 0.978 0.978 0.978
Space group P21212 P21212 P3121
Cell constants (A˚) a=78.7, b=118.9, c=42.1 a=91.4, b=119.9, c=30.9 a=99.1, b=99.1, c=66.5
Resolution (A˚) 2.32 (40.00–2.32) 1.83 (40.00–1.83) 2.30 (40.0–2.30)
Completeness (%) 99.9 (99.9) 96.0 (98.4) 100.0 (99.6)
Total no. of reﬂections 556 100 524 555 670 642
No. of unique reﬂections 17 973 31 246 17 079
Redundancy 2.4 (2.5) 2.7 (2.9) 3.1 (3.2)
Rmerge (%) 36.4 (7.7) 39.8 (4.9) 36.4 (5.7)
(I/(I)) 2.17 (11.65) 2.08 (23.47) 2.94 (26.33)
Phasing
Selenium atom sites 2
Resolution range of data used (A˚) 40.00–2.32
Figure of merit (acentric/centric) 56.1/42.4
Reﬁnement
Rwork (%) 20.28 20.40 20.59
Rfree (%) 27.06 24.71 26.16
B-factors
Overall (A˚2) 38.5 24.6 48.0
Protein chain A/B (A˚2) 39.0/36.9 25.8/23.3 45.8/50.3
Ligand chain A/B (A˚2) – – 37.0/36.6
Water (A˚) 39.2 29.3 41.1
No. of atoms in protein chain A/B 1329/1329 1321/1321 1322/1329
No. of ligands 0 0 2
No. of waters 77 67 64
Rms deviations
Bond angles () 1.1 0.9 1.0
Bond length (A˚) 0.008 0.007 0.008
Ramachandran analysis
Most favored regions (%) 94.9 94.3 94.2
Allowed regions (%) 5.1 5.7 5.8
Generously allowed regions (%) 0.0 0.0 0.0
Disallowed regions (%) 0.0 0.0 0.0
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Coot (22). Then, the model was reﬁned using translation/
libration/screw (TLS) reﬁnement techniques adopting a
single TLS body as implemented in PHENIX (21)
leaving 5% of reﬂections in Free-R set. Iterations of re-
ﬁnement using PHENIX (21) and CNS (23) and model
building in Coot (22) lead to the current model, which
consists of 173 residues (residues 12–184) with excellent
geometrical characteristics (Table 1).
The Form II and Rv3066–ethidium crystals took the
space groups P21212 and P3121, respectively. These two
structures were phased using the molecular replacement
(MR) program PHASER (19) by using the Form I struc-
ture as the search model. Structural reﬁnements were then
performed using PHENIX (21) and CNS (23) (Table 1).
Electrophoretic mobility shift assay
To determine the binding of Rv3066 to the operator
region of mmr, electrophoretic mobility shift assay
(EMSA) was performed according to the procedure des-
cribed by Alekshun et al. (24). The 30-bp oligonucleotide,
50-CGAGCCTCCTTTGTGTACATTTGTACATGT-30,
containing the hypothetical operator site IR1 was labeled
at the 30-end with digoxigenin-11-ddUTP (DIG-
11-ddUTP) using the DIG Gel Shift Kit (Roche Applied
Science, Indianapolis, IN, USA). A random 30-bp internal
rv3066 fragment was used as the control DNA for the gel
shift assay. This control DNA fragment was also labeled
with DIG-11-ddUTP. The DIG-11-ddUTP-labeled DNA
fragments (0.02 mM) were incubated with the puriﬁed
Rv3066 protein at concentrations ranging from 0.04 to
0.64 mM in binding buffer composed of 20mM HEPES,
pH 7.6, 1mM EDTA, 10mM (NH4)2SO4, 5mM
dithiothreitol, 0.2% Tween 20 (wt/vol), 30mM KCl and
0.5 mg of Poly [d(I-C)] as a non-speciﬁc competitor. The
reaction mixtures were incubated at room temperature for
30min and then subjected to electrophoresis on a 7.5%
(wt/vol) non-denaturing polyacrylamide gel at 150V for
30min. The DNA complexes in the gel were transferred to
a nylon membrane with a vacuum blotter. The DIG-
labeled DNA was detected and visualized using antidi-
goxigenin antibody and the chemiluminescent substrate
CDP-star (Roche Applied Science). For the competition
experiments, different amounts (5- and 125-fold molar
excesses) of either unlabeled 30-bp DNA or unlabeled
internal random DNA were added as competitors during
the binding step. The ligand-binding assays were done by
incubating different concentrations of ethidium bromide
(6.4, 64, 320, 640 and 1280 mM) with the puriﬁed Rv3066
protein for 30min before adding the labeled
double-stranded DNA (dsDNA) fragments for the
experiments.
Dye primer based DNase I footprint assay
The DNase I footprint assay was performed as described
by Zianni et al. (25). A 226-bp fragment that encom-
passes bases 153 to +87, including IR1 (with the
sequence of IR2 removed), of the promoter region of
mmr was generated by PCR and cloned into the
pGEM-Teasy vector. The ﬂuorescently labeled probe
was ampliﬁed using the primers 6FAM-Mmr-F
(50-/6FAM/tcgagatctttcaccatg-30) and HEX-Mmr-R
(50-/HEX/caaccgagtgaacccttc-30). An amount of 0.6 pmol
of the gel puriﬁed ﬂuorescently labeled probe was
incubated with various amounts of the dimeric Rv3066
protein (0, 1.5 and 3.0 pmol) for 30min at room tempera-
ture in a binding buffer containing 20mM HEPES,
pH 7.6, 10mM (NH4)2SO4, 5mM dithiothreitol, 0.2%
Tween 20 (wt/vol), 30mM KCl and 0.5 mg of Poly
[d(I-C)]. Bovine serum albumin (BSA) was used for the
control experiment. After incubation, 10mM MgCl2 and
5mM CaCl2 were added to the reaction mixture to a ﬁnal
volume of 50 ml. Then, 0.0025 U of DNase I (Worthington
Biochemicals, Lakewood, NJ, USA) was added
and incubated for 5min at room temperature. The
reaction was stopped by adding 0.25M EDTA and ex-
tracted with phenol:chloroform:isoamylalcohol (25:24:1).
Control digestions with the probe were performed in the
absence of Rv3066. The digested DNA fragments were
puriﬁed with the QIAqick PCR Puriﬁcation kit (Qiagen,
Valencia, CA, USA) and eluted in 20 ml distilled water.
After, 4 ml of the puriﬁed DNA was mixed with 5.98 ml
HiDi formamide (Applied Biosystems, Foster City, CA,
USA) and 0.02ml GeneScan-500 LIZ size standards
(Applied Biosystems). The samples were analyzed with
the 3730 DNA analyzer coupled by G5 dye set, using an
altered default genotyping module that increased the
injection time to 30 s and the injection voltage to 3 kV.
The 226-bp fragment was sequenced with the primers
6FAM-Mmr-F and HEX-Mmr-R, respectively, using the
Thermo Sequenase Dye Primer Manual Cycle Sequencing
Kit (USB, Inc., Cleveland, OH, USA) according to the
manufacturer’s instructions. Each reaction was diluted
5-fold in water, and 4 ml was added to 5.98ml HiDi
formamide and 0.02ml GeneScan-500LIZ size standard.
The samples were analyzed using the 3730 DNA
analyzer as described above. Electropherograms were
analyzed and aligned using the GENEMAPPER
software (version 4.0, Applied Biosystems).
Cloning of the M. tuberculosis mmr-rv3066 operon into
Mycobacterium smegmatis
Primer pairs (FP: CGCGGATCCATCTTTCACCATGA
CACGAC, RP: CCCAAGCTTAGGACTGGTATTCGG
CGGTT) with added BamHI and HindIII sites
were used to amplify the complete mmr-rv3066 operon
(including the promoter region) from M. tuberculosis
H37Rv genomic DNA. The ampliﬁed fragment was
digested and ligated into E. coli–Mycobacterium shuttle
vector pMV261 (kindly provided by Susan T. Howard,
The University of Texas Health Science Center) to con-
struct pMMR. pMV261 is a shuttle plasmid commonly
used for cloning and expression of genes in mycobacteria.
The cloned mmr-rv3066 operon carried its own promoter
sequence. Although there should be constitutive base-level
expression from the vector, mmr is inducible due to the
binding of drug by the regulator. The constructed pMMR
in E. coli DH5a was then puriﬁed and electroporated into
M. smegmatis mc2155 (ATCC700084) (26).
Nucleic Acids Research, 2012, Vol. 40, No. 18 9343
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Real-time quantitative reverse transcriptase–PCR
analysis of mmr induction
Mycobacterium smegmatis mc2155 strain containing
pMMR was inoculated into 30ml of antibiotic-free 7H9
broth. The culture was incubated for overnight to the mid
logarithmic phase (OD600 & 0.6) at 37C. The culture was
divided into four aliquots. One aliquot was used as the
non-treated control, while the other three were added
with thioridazine (80mg/ml), erythromycin (128mg/ml)
and ethidium bromide (10mg/ml), respectively. The
cultures were further incubated for 1 h at 37C. Total
bacteria RNA was isolated from the three individual
cultures by the Trizol method (27). RNA was further
puriﬁed by Qiagen RNeasy Column (Qiagen) and
treated with the Turbo DNA-free Kit (Life
Technologies, Grand Island, NY, USA) to eliminate
DNA contamination in each preparation. Before being
used for quantitative reverse transcriptase–PCR (qRT–
PCR), each RNA template and each primer set were
tested with a conventional one-step RT–PCR kit and a
regular PCR kit (Life Technologies) to ensure speciﬁc
ampliﬁcation from the target mRNA and no detectable
DNA contamination in the RNA preparation. Primer
pairs 3065F (50-CCTATACCTCTTGTGCGCGAT-30)
and 3065R (50-CGAAAGCGATGCCATAACCC-30),
speciﬁc for the mmr gene were designed for qRT–PCR
analyses, which were conducted using the iScript
one-step RT–PCR kit with SYBR green (Bio-Rad,
Hercules, CA, USA) along with the MyiQ iCycler
real-time PCR detection system (Bio-Rad). Triplicate re-
actions in a volume of 15 ml were performed for each
dilution of the RNA template. Thermal cycling conditions
were as follows: 10min at 50C, 5min at 60C followed by
5min at 95C and then 40 cycles of 10 s at 95C and 30 s at
56C. Melt-curve analysis was performed immediately fol-
lowing each ampliﬁcation. Samples between treatments
were normalized using the aph gene which was
located on the pMV261 vector as an internal standard.
Cycle threshold values were determined with the MyiQ
software (Bio-Rad). The relative changes (n-fold) in mmr
transcription between the antibiotic treated and
nontreated samples were calculated using 2-CT
method as described by Livak and Schmitten (28).
Site-directed mutagenesis
Site-directed point mutations on residues that are expected
to be critical for the binding of drugs were performed to
generate single point mutants, W80A, Y101A, N112A,
Y115A, W131A and D156A, and a double-point mutant
W80A–W131A. The primers used for these mutations are
listed in Table 2. All oligonucleotides were purchased
from (Integrated DNA Technologies, Inc., Coralville,
IA, USA) in a salt-free grade.
Fluorescence polarization assay for the
DNA-binding afﬁnity
Fluorescence polarization assays were used to determine
the DNA-binding afﬁnity of the Rv3066 regulator. Both
the 30-bp oligodeoxynucleotide- and ﬂuorescein-labeled
oligodeoxynucleotide were purchased from Integrated
DNA Technologies, Inc. These oligodeoxynucleotides
contain the predicted 14-bp IR1 site for Rv3066 binding.
Their sequences were 50-CGAGCCTCCTTTGTGTACA
TTTGTACATGT-30 and 50-F-ACATGTACAAATGTAC
ACAAAGGAGGCTCG-30, where F denotes the ﬂuores-
cein which was covalently attached to the 50-end of the
oligodeoxynucleotide by a hexamethylene linker. The
30-bp ﬂuoresceinated dsDNA was prepared by annealing
these two oligodeoxynucleotides together. Fluorescence
polarization experiment was done using a DNA-binding
solution containing 10mM Na-phosphate (pH 7.2),
100mM NaCl, 1 nM ﬂuoresceinated DNA and 1 mg of
poly(dI-dC) as non-speciﬁc DNA. The protein solution
containing 500 nM dimeric Rv3066 and 1 nM ﬂuores-
ceinated DNA was titrated into the DNA-binding
solution until the millipolarization (mP) became un-
changed. All measurements were performed at 25C using
a PerkinElmer LS55 spectroﬂuorometer equipped with a
Hamamatsu R928 photomultiplier. The excitation wave-
length was 490 nm, and the ﬂuorescence polarization
signal (in P) was measured at 520nm. Each titration point
recorded was an average of 15 measurements. Data were
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analyzed using the equation, P={(PboundPfree)
[protein]/(KD+[protein])}+Pfree, where P is the polariza-
tionmeasured at a given total protein concentration,Pfree is
the initial polarization of free ﬂuorescein-labeled DNA,
Pbound is the maximum polarization of speciﬁcally bound
DNA and [protein] is the protein concentration. The titra-
tion experiments were repeated for three times to obtain
the average KD value. Curve ﬁtting was accomplished
using the program ORIGIN (OriginLab Corporation,
Northampton, MA, USA).
To study if the binding afﬁnity between Rv3066 and
DNA is affected by ethidium, ﬂuorescence polarization
experiment was carried out in the presence of 1 mM eth-
idium. All experimental procedures were the same as
above, except that the protein and DNA-binding solutions
also contain 1 mM ethidium.
Fluorescence polarization assay for
ligand-binding afﬁnity
Fluorescence polarization was used to determine
ethidium-binding afﬁnities of Rv3066 and its mutants.
This approach was also employed to study the interaction
between the Rv3066 regulator and the anti-TB drug thi-
oridazine. The experiment was done using a ligand-
binding solution containing 10mM Na-phosphate
(pH 7.2), 100mM NaCl and 1 mM ethidium bromide.
The protein solution consisting of Rv3066 or Rv3066
mutant in 10mM Na-phosphate (pH 7.2), 100mM NaCl
and 1 mM ethidium bromide was titrated into the ligand-
binding solution until the polarization (P) was unchanged.
As this is a steady-state approach, ﬂuorescence polariza-
tion measurement was taken after a 5min incubation for
each corresponding concentration of the protein and
ligand to ensure that the binding has reached equilibrium.
All measurements were performed at 25C using a
PerkinElmer LS55 spectroﬂuorometer equipped with a
Hamamatsu R928 photomultiplier. The excitation and
emission wavelengths were 483 and 620 nm for ethidium
binding, whereas these wavelengths were 320 and 430 nm
for thioridazine measurement. Fluorescence polarization
signal (in P) was measured at the emission wavelength.
Each titration point recorded was an average of 15 meas-
urements. Data were analyzed using the equation,
P={(PboundPfree)[protein]/(KD+[protein])} + Pfree,
where P is the polarization measured at a given total
protein concentration, Pfree is the initial polarization of
free ligand, Pbound is the maximum polarization of specif-
ically bound ligand and [protein] is the protein concentra-
tion. The titration experiments were repeated for three
times to obtain the average KD value. Curve ﬁtting was
accomplished using the program ORIGIN (OriginLab
Corporation).
Gel ﬁltration
A protein liquid chromatography Superdex 200 16/60
column (GE Healthcare Biosciences) with a mobile
phase containing 20mM Tris–HCl (pH 8.5) and 300mM
NaCl was used in the gel-ﬁltration experiments. Blue
dextran (Sigma-Aldrich, St Louis, MO, USA) was used
to determine the column void volume, and proteins for
use as gel ﬁltration molecular weight standards were cyto-
chrome C (Mr 12 400), carbonic anhydrase (Mr 29 000),
albumin bovine serum (Mr 66 000), alcohol dehydrogenase
(Mr 150 000) and b-Amylase (Mr 200 000). All these stand-
ards were purchased from Sigma-Aldrich. The molecular
weights of the experimental samples were determined fol-
lowing the protocols supplied by the manufacturers.
Molecular modeling
The program AutoDock Vina (29) was used to predict the
ligand-binding mode of several Rv3066 drugs, including
acriﬂavine, ethidium, proﬂavine, pyronin Y, safranin O
and thioridazine. A monomer of the structure of
Rv3066–ethidium with the bound ethidium removed was
used for dockings. The protein was set as a rigid structure
whereas the conformation of each ligand was optimized
during all modeling and docking procedures. For each
ligand, the results were ranked on the basis of predicted
free energy of binding and the one with the highest
binding afﬁnity was recorded.
The model of the DNA-bound form of Rv3066 was
generated using AutoDock Vina (29). In brief, the two
N-terminal domains of dimeric apo-Rv3066 (Form I
structure) were chosen to dock onto the two successive
major grooves of the IR1 double helix. During the
docking procedure, both the structures of Rv3066 and
IR1 were held rigid. After obtaining the docking result,
the entire structure of the dimeric Rv3066 regulator was
then superimposed onto the docked N-terminal helices at
the major grooves of the DNA to generate the ﬁnal
Rv3066–DNA complex model.
RESULTS
Overall structure of Rv3066
In the absence of inducer molecule, the Rv3066 regulator
was crystallized in two different Forms, I and II
(Supplementary Figure S1). The Form I (SeMet) crystal
structure was determined to a resolution of 2.3 A˚ (Table 1
and Figure 1a). The asymmetric unit contains a single
homodimer, suggesting that this regulator is dimeric in
nature. Similar to LfrR (30), the left and right subunits
of Rv3066 are asymmetrical. The dimeric Form I structure
of Rv3066, indicating an all-helical protein, is shown in
Figure 1b. Superimposition of both subunits of Rv3066
gives rise to an overall rms deviation of 1.3 A˚ calculated
over the Ca atoms.
The crystal structure of Form II was reﬁned to a reso-
lution of 1.8 A˚ (Table 1). Like Form I, the structure of
Form II indicates that this protein is an asymmetric
homodimer. Superimposition of the Ca atoms of the
two subunits of Form II results in an rms deviation of
1.8 A˚. Surprisingly, the conformations of the structures
of Forms I and II are quite distinct from each other,
suggesting that these two structures probably represent
two different transient states of the regulators.
Superimposition of the entire dimer of these two apo-
Rv3066 structures (Forms I and II) provides an rms devi-
ation of 3.0 A˚ (Figure 2). Overall, the architecture of these
two Rv3066 structures are in good agreement with those
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of the homolog proteins TetR (31,32), QacR (33,34), CprB
(35), EthR (36,37), CmeR (38), AcrR (39), SmeT (40)
and LfrR (30). Each subunit of Rv3066 is composed of
nine a helices (a1–a9 and a10–a90, respectively) (Figures 1b
and 2) and can be divided into two motifs: an N-terminal
DNA-binding domain and a C-terminal ligand-binding
domain. The helices of Rv3066 are designated numerically
from the N-terminus as a1 (15–30), a2 (37–44), a3 (48–54),
a4 (58–86), a5 (90–103), a6 (105–120), a7 (122–143), a8
(145–165) and a9 (171–182). In this arrangement, the
smaller N-terminal domain includes helices a1 through
a3 and the N-terminal end of a4 (residues 58–68), with
a2 and a3 forming a typical helix-turn-helix motif.
However, the larger C-terminal domain comprises the
C-terminal end of helices a4 (residues 69–86) through a9
and helices a6, a8 and a9 are involved in the dimerization
of the regulator. The smaller N-terminal domain shares
considerably high sequence and structural similarities
with the TetR-family regulators, suggesting that Rv3066
belongs to the TetR family. For example, residues 13–68
possess 20% amino acid identity and 68% homology to
that of TetR (31). This N-terminal region also shows
identities of 29% and 25%, and similarities of 62% and
63% to those of the M. smegmatis LfrR (30) and
M. tuberculosis EthR repressors (37), respectively.
Protein sequence alignment of Rv3066 with the TetR-
family members of other Mycobacterium species is
shown in Supplementary Figure S2. The alignment
suggests that Rv3066 is a typical TetR-family regulator.
Conformational ﬂexibility of the Rv3066 regulator
Two distinct conformations of apo-Rv3066 were captured
using crystallography, suggesting that this regulatory
protein is quite ﬂexible in nature. A comparison of the
N-terminal DNA-binding domains of the dimeric struc-
tures of Forms I and II indicates that these two structures
may depict two different transient states of the regulator.
Apparently, these two conformations are related in which
an 8 rotational motion of the right subunit (helices a10–
a90) with respect to the left protomer (helices a1–a9) is
attributed to the difference (Supplementary Figure S3).
(a)
(b)
Figure 1. Stereo view of the experimental density map and ribbon diagram of the crystal structure of Rv3066. (a) Representative section of electron
density in the vicinity of helices a5 and a8. The solvent-ﬂattened electron density (40–2.3 A˚) is contoured at 1s and superimposed with the ﬁnal
reﬁned model (magenta, carbon; red, oxygen; blue nitrogen). (b) Ribbon diagram of the Rv3066 dimer. Helices a1–a9 (left subunit) and a10–a90
(right subunit) are labeled. The Figure was prepared using PyMOL (http://www.pymol.sourceforge.net).
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Indeed, we can easily generate the Form II conformation
using the Form I structure as a starting point and then
following the rigid-body rotational trajectory based on the
TLS parameters. The resulting ﬁnal B-factors and overall
Rwork/Rfree of this Form II dimeric Rv3066 structure are
24.0/22.9 A˚2 (left/right subunits) and 21.4/25.5%, respect-
ively. Thus, there is a chance that ligand binding triggers a
rotational motion within the dimer of the regulator.
Presumably, this movement prohibits the binding of the
dimeric regulator at its cognate DNA, which in turn
releases the regulator from the promoter region and
allows for the expression of the Mmr efﬂux pump.
The C-terminal domain of the Form II structure forms
a large cavity, presumably creating a ligand-binding
pocket of the regulator (Supplementary Figure S4). This
cavity cannot be found in the Form I structure. Thus, it is
likely that the Form II crystal structure mimics the
ligand-bound form of Rv3066. The pocket, predominately
formed by helices 5–8, opens horizontally from the side of
each protomer. The total volume of these two binding
pocket is about 540 A˚3 (230 A˚3 for the left subunit and
310 A˚3 for the right subunit). Helices a4–a6 of each
subunit of Form II make the entrance of the binding
pocket, with residues V100, D104 and Y108 participating
to form this entrance.
Structure of the Rv3066–ethidium complex
The crystal structure of the Rv3066–ethidium complex
(Figures 3 and Supplementary Figure S5) was reﬁned to
a resolution of 2.3 A˚ (Table 1), revealing that ethidium
indeed binds within the ligand-binding pocket formed by
the C-terminal domain. Helices 5–8 contribute to form
this pocket, and each subunit of Rv3066 is found
to bind an ethidium molecule within the binding pocket.
Superimposition of the dimeric Rv3066–ethidium
structure to those of Forms I and II apo-Rv3066 result
in overall rms deviations of 3.4 and 1.9 A˚, respectively.
Although the conformations of the two subunits within
the dimer are not identical, their ethidium-binding modes
are quite similar. Both ethidium sites utilize the same set of
amino acids to accommodate the binding, with a slight
difference in the interaction distances. The FoFc
electron density maps of the two bound ethidiums
within the dimer are illustrated in Figure 4a. Interestingly,
the total volume of the two ligand-binding pocket has
expanded to 929 A˚3 (443 A˚3 for the left subunit and 486
A˚3 for the right subunit) in the ethidium bound structure.
Each bound ethidium molecule is completely buried in
the Rv3066-binding pocket. The ligand-binding pocket is
found to be hydrophobic in nature. Five aromatic
residues, W80, Y101, Y115, W131 and F155, participate
to make aromatic stacking interactions and hydrophobic
contacts with the bound ethidium (Figure 4b and c and
Supplementary Figure S6). In addition, L76, T98, L111
and T159 are involved to secure the binding through
hydrophobic interaction. Furthermore, the N1 and N2
amino group nitrogens of the phenanthridinium system
of ethidium are hydrogen bonded to the side chain
oxygen of T159 and S73 respectively (Table 3).
Additional hydrogen bonds have also been found
between the N1 and N2 amino group nitrogens of the
bound ethidium and the backbone oxygens of F155 and
S73 to secure the binding (Table 3). In addition, a nega-
tively charged residue D156 participates to form the
ligand-binding site, and this residue is 3.3 A˚ away from
the phenyl groups of the bound ethidium in each subunit
of the dimer (Figure 4b and Supplementary Figure S6).
Electrophoretic mobility shift assay
Bacterial multidrug efﬂux regulators usually bind to the
palindromic IR sequences at the promoter regions to
control the expression of the multidrug efﬂux pumps. In
the mmr-rv3066 operon, it appears that there are two
14-bp palindromic IR sequences located upstream of
mmr. These two IRs (IR1 and IR2) are located right
next to one another, where their sequences are comple-
mentary to each other (Supplementary Figure S7). The
sequences of IR1 and IR2 are 50-TGTACATTTGTACA-
30 and 50-TGTACAAATGTACA-30, respectively. The
presence of these IRs suggests potential binding sites for
the Rv3066 regulator. Thus, EMSA was performed using
a 30-bp dsDNA containing the IR1 sequence and puriﬁed
Rv3066 protein to detect if the regulator speciﬁcally binds
IR1. As shown in Figure 5a and b, the shift of the labeled
DNA band was dependent upon the protein concentration
as well as the addition of the unlabeled speciﬁc 30-bp
dsDNA. The data indicate that the IR1 sequence poten-
tially forms the speciﬁc binding site for Rv3066.
EMSA was further performed with the puriﬁed Rv3066
protein and 30-bp DNA fragment containing the IR1 site
in the presence of ethidium, which is a substrate of the
Mmr efﬂux pump and is found to be bound in the ligand-
binding site of the Rv3066 regulator. As shown in
Figure 5c, the addition of ethidium to the Rv3066–DNA
complex resulted in the loss of the retarded band,
Figure 2. Structural comparison of Forms I and II of the Rv3066 regu-
lator. This is a superimposition of the dimeric structures of Forms
I and II (orange, Form I; blue, Form II). Helices a1–a9 (left subunit)
and a10–a90 (right subunit) are labeled. The arrow indicates a change in
orientation of the right subunit of Form II when compared with the
structure of Form I.
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indicating the separation of the protein and DNA compo-
nents. The result suggests that ethidium is a substrate of
Rv3066 and that the binding of ethidium triggers signiﬁ-
cant conformational change to the regulator, which in
turn renders it unable to bind its cognate operator DNA.
Dye primer based DNase I footprint assay
To further conﬁrm the binding site of Rv3066 in the
mmr-rv3066 promoter region, DNase I footprint assay
was performed using the method of dye primer sequencing
(25). In comparison with different electropherograms at
various concentrations of the dimeric Rv3066 protein,
we were able to uncover the speciﬁc DNA sequence,
TTGTGTACATTTGTACACAAAGG, which was pro-
tected by the regulator (Figure 6 and Supplementary
Figure S8). Interestingly, the IR1 sequence (TGTACA
TTTGTACA) was found within this protected region, sug-
gesting that Rv3066 is likely to speciﬁcally bind IR1.
Impact of drugs on mmr transcription in M. smegmatis
We cloned the mmr-rv3066 operon into M. smegmatis to
assess its function and induction by antimicrobials. It has
(a)
(b)
Figure 3. Crystal structure of the Rv3066–ethidium complex. (a) Ribbon diagram of the Rv3066–ethidium complex. The bound ethidiums are shown
as sticks (magenta, carbon; blue, nitrogen). (b) Structural comparison of Form I and Rv3066–ethidium. This is a superimposition of the dimeric
structures of Form I (orange) and Rv3066–ethidium (green). The bound ethidiums are in yellow sticks. Helices a1–a9 (left subunit) and a10–a90
(right subunit) are labeled. The arrow indicates a change in orientation of the right subunit of dimeric Rv3066–ethidium when compared with the
Form I structure. This conformational change can be interpreted as a rotational motion of the right subunit of Rv3066 with respect to the horizontal
axis passing through the two ligand-binding pockets of the dimer upon ethidium binding.
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been reported that the anti-TB drug thioridazine was used
to cure 10 XDR-TB patients (41). Thus, this drug was
chosen to investigate its effect on the expression of the
Mmr multidrug efﬂux pump using qRT–PCR. We also
studied the effect of ethidium and erythromycin on mmr
transcription using the same approach. After 1 h induction
with thioridazine, the mmr gene was up-regulated by
2.70±0.09-fold (P-value=0.0001). No obvious induc-
tion of the mmr gene was observed in the presence of
ethidium or erythromycin at the same time-point.
Fluorescence polarization assay
Presumably, Rv3066 suppresses the expression of the
Mmr multidrug efﬂux pump by directly binding to its
target DNA. Fluorescence polarization-based assay was
carried out to study the interaction between Rv3066 and
the 30-bp DNA containing the IR1 sequence. Figure 7a
illustrates the binding isotherm of Rv3066 in the presence
of 1 nM ﬂuoresceinated DNA. The titration experi-
ment indicated that this regulator binds the 30-bp
IR1 operator with a dissociation constant, KD, of
4.4±0.3 nM. This value is similar to that of the QacR
regulator where it binds DNA with the KD of 5.7 nM
(42). The binding data also indicate that Rv3066 binds
its cognate DNA with a stoichiometry of one Rv3066
dimer per IR1.
To investigate whether the presence of ethidium affects
the binding of Rv3066 with IR1, ﬂuorescence polarization
was also carried out to study the interaction between
Rv3066 and IR1 in the presence of this drug. The experi-
mental results suggest that the KD of Rv3066–IR1
becomes 10.7±0.9 nM in the presence of 1 mM ethidium
(Supplementary Figure S9), indicating that ethidium sig-
niﬁcantly weakens the binding afﬁnity between Rv3066
and IR1 by 2.4 times.
In addition, ﬂuorescence polarization was used to
determine the binding afﬁnity of ethidium and the
anti-TB drug thioridazine by Rv3066. The measurements




Figure 4. Electron density maps and the ethidium-binding site.
(a) Stereo view of the FoFc electron density map of the bound
ethidium in the left subunit of dimeric Rv3066 (the orientation corres-
ponds to Figure 3a). The bound ethidium is shown as a stick model
(magenta, carbon; blue, nitrogen). The FoFc map is contoured at 3.0
s (blue mesh). The surrounding secondary structural elements are
shown as yellow ribbons. (b) The ethidium-binding site of the left
subunit of the dimeric Rv3066–ethidium complex. Residues involved
in ethidium binding are in green sticks. The bound ethidium is shown
as yellow sticks. Dotted lines depict the hydrogen bonds. (c) Superim-
position of the ligand-binding pocket before and after ethidium
binding. Residues involved in ethidium binding are shown as sticks
(orange, Form I; green, Rv3066–ethidium).
Table 3. Rv3066–ethidium contacts
Distance (A˚)
Residue–ligand contacts A chain B chain
S73 2.7a 2.7a










F155 (backbone oxygen) 2.9a 2.7a
D156 3.3 3.3
T159 2.9a 2.7a
Contacts within 4.8 A˚ of the bound ethidiums are listed.
aHydrogen bond distance.
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Rv3066–thioridazine complexes are 2.9±0.2 and
211.8±34.2mM, respectively (Figure 7b and c). These
binding data suggest that the protein employs a simple
binding stoichiometry with a 1:1 monomeric Rv3066-
to-drug molar ratio. This molar ratio is indeed in good
agreement with the crystal structure where each monomer
of Rv3066 binds one ethidium molecule.
The structure of Rv3066–ethidium indicates that
residues W80, Y101, N112, Y115, W131 and D156 are
involved in ligand binding. These residues were mutated
into alanines (W80A, Y101A, N112A, Y115A, W131A
and D156A). The corresponding mutant regulators were
then expressed and puriﬁed. The ability of these mutant
regulators to bind ethidium was tested using ﬂuorescence
polarization assay (Table 4). The results demonstrate that
several of these point mutants show a signiﬁcant decrease
in the binding afﬁnity for ethidium when compared with
the wild-type Rv3066 regulator. Particularly, mutant
D156A increases the dissociation constant, KD, of
ethidium binding by 20-fold, suggesting that D156 is a
critical residue in the multidrug-binding site of Rv3066.
Moreover, mutants W80A, N112A and W131A decrease
the afﬁnity for ethidium binding by three to four times. A
double-point mutant W80A–W131A was then produced
to investigate how these tryptophans affect the binding
of ethidium. Similar to the D156A mutant, the W80A–
W131A double mutant indicates a signiﬁcantly weaker
binding afﬁnity (20-fold decrease) when compared with
that of the wild-type Rv3066, suggesting these two tryp-
tophans, W80 and W131, are important residues for drug
recognition.
Gel ﬁltration
To conﬁrm the stoichiometry of one Rv3066 dimer bound
to one IR1 operator site, gel-ﬁltration experiment was
performed using the puriﬁed Rv3066 protein pre-
incubated with the puriﬁed, complementary, annealed
30-bp oligonucleotides containing the IR1 sequence.
The result suggests an average molecular weight of
67.3±3.8 kDa for the Rv3066–DNA complex
(Figure 8). This value is in good agreement with the the-
oretical value of 66.0 kDa for two Rv3066 molecules
bound to the 30-bp DNA. Thus, the stoichiometry of
the Rv3066–IR1 complex is 1:1 dimeric Rv3066-to-DNA
molar ratio.
Docking of ligands into the multidrug drug binding site
To understand how Rv3066 binds different ligands, we
used the program AutoDock Vina (29) to identify poten-
tial binding modes for a variety of drug molecules.
We ﬁrst predicted an ethidium-binding site in Rv3066.
We found that the predicted bound ethidium molecule
was completely overlapped with the bound ethidium
identiﬁed from the crystal structure and their binding
modes are nearly identical (Supplementary Figure S10),
suggesting that AutoDock Vina is sufﬁciently precise for
identiﬁcation of potential drug-binding pockets. When
Vina was used to search for binding sites for different
Rv3066 drugs, including acriﬂavine, proﬂavine, pyronin




Figure 5. Electrophoretic mobility shift assay for Rv3066 and IR1
binding. (a) The DIG-11-dUTP-labeled DNA (0.02 mM) was incubated
with increasing concentrations (0, 0.04, 0.16 and 0.64 mM) of the
puriﬁed Rv3066 protein (lanes 1–4, respectively). With Rv3066 at
0.64mM, the binding was competed by the unlabeled 30-bp DNA
(0.10 and 2.50mM, lanes 5 and 6, respectively), and unlabeled
internal random DNA fragment (0.10 and 2.50 mM, lanes 7 and 8,
respectively). (b) Control experiment of EMSA. The control experi-
ments were performed using 0.02mM labeled internal random DNA
with different concentrations of the Rv3066 regulator (0, 0.64 and
1.28mM, lanes 1, 2 and 3, respectively). (c) Ethidium bromide dissoci-
ates the Rv3066–IR1 complex. Different concentrations (0, 6.4, 64, 320
and 1280mM) of ethidium bromide were incubated with 0.64mM of
puriﬁed Rv3066 (lanes 2–7, respectively) for 30min before adding the
DIG-11-dUTP-labeled 30-bp DNA (0.02 mM) for the assays. Lane 1
indicates the signal of the free DIG-11-dUTP-labeled DNA.
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all these drug molecules were bound within the
ethidium-binding site identiﬁed by X-ray crystallography
(Figure 9a and Table 5).
Predicting the structure of DNA-bound form of Rv3066
AutoDock Vina (29) was also used to generate a model of
the Rv3066–DNA complex structure (Figure 9b and
Table 5). This model reveals that the two N-terminal
domains of Rv3066 within the dimer are able to ﬁt well
into the two successive major grooves of the target DNA.
Extensive interactions between the regulator and
DNA have also been found to stabilize this protein–
DNA complex structure. Speciﬁcally, T52 is found to
make a contact with one base of IR1. In addition, Y53
participates to interact directly with two different bases.
Additional stabilization of the complex comes from R15,
H37 and R38, in which these residues make phosphate
contacts with the DNA.
DISCUSSION
With the rising incidences of multidrug resistant strains of
TB, it has become increasingly important to understand
how individual proteins function to recognize and confer
resistance to multiple antibiotics in this pathogen. The
crystal structures of Rv3066 both in the absence and
presence of the bound ethidium provide direct information
about how this regulator controls the expression of the Mmr
multidrug efﬂux pump, which mediates the resistance of
several antimicrobial agents. It appears that ethidium
binding triggers a series of cooperativity motions of the
C-terminal helices, including the horizontal shifts of helices
a5, a6 and a7 toward the dimer interface, and an upward
movement of helix a8 within one subunit of the regulator.
These conformational changes initiate a rotational motion
of the second subunit of Rv3066 with respect to the hori-
zontal axis passing through the two ligand-binding pockets
of the dimer (Figures 3b, 5a and b), presumably making
the relative orientation of the two N-terminal
DNA-binding domains no longer compatible with the two
consecutive major grooves of the operator B-DNA. The net
result is that this dimeric regulator is released from the
promoter, initiating the expression of the Mmr multidrug
efﬂux pump.
We generated a speculative model of DNA-bound
Rv3066 using AutoDock Vina (29). The model suggests
that the two N-terminal DNA-binding domains of the
dimeric apo-Rv3066 regulator (Form I) can easily be
docked onto the two consecutive major groove of IR1,
suggesting that the structure of the regulator in the
Rv3066–IR1 complex may be very similar to the Form I
structure of apo-Rv3066. By comparing with the
apo-Rv3066, Rv3066–ethidium and the speculative
Rv3066–DNA structures, it appears that the induction
mechanism of Rv3066 seems to be attributed to the rigid
body rotational motion of the two subunits triggered by
ethidium binding (Figure 5c). As mentioned above, this
motion changes the relative orientation of the two
DNA-binding domains of Rv3066, which makes the




Figure 6. Direct binding of Rv3066 to the mmr-rv3066 promoter by dye primer based DNase I footprint assay. Electropherograms indicating the
protection pattern of the mmr-rv3066 promoter after digestion with DNase I following incubation with (a) 0, (b) 1.5 and (c) 3.0 pmol of dimeric
Rv3066 are shown. The protected DNA sequence TTGTGTACATTTGTACACAAAGG containing IR1 is also shown.
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grooves of the IR and results in disallowing the regulator
to bind the DNA duplex. This induction mechanism is
quite distinct from those of QacR (33,34) and TetR
(31,32). However, a similar induction mechanism, which
is triggered by the movement as rigid bodies, can be found
in the SimR regulator (43), where rigid body rotation
within subunits of the dimer in relation to one another
contributes to the induction.
In comparison with the Form I and ethidium bound
structures, the shift in position of helices a5, a6 and a7
toward the dimer interface results in the formation of four
new hydrogen bonds. These hydrogen bonds are found
within the dimer interface between H120 and R1090, and
between R121 and Q1130. In addition, the backbone
oxygens of R129 and T165 also contribute to the dimer
interface. These backbone oxygens interact with I1640 and
R1290 to form two hydrogen bonds. The formation of
these new hydrogen bonds is presumed to stabilize the
tertiary structure of the ligand bound form of the
Rv3066 dimer.
Coupled with the movements of these C-terminal
helices, residues located at the binding site are also
found to readjust their positions to accommodate for the
binding of ethidium. Noticeably, Y115 shifts upward by
2.4 A˚ presumed to make an interaction with the phenyl
group of the bound ethidium, whereas F155 is found to
swing upward by 90 to enlarge the volume of the binding
site. In addition, W131 adjusts its position to shift upward
by 2.3 A˚ and makes an aromatic stacking interaction with
the three-ring system of the phenanthridinium group of
ethidium. W80 and Y101 also slightly switch in location
by 1.1 and 2.0 A˚ to contribute aromatic p–p and stacking
interactions with the bound ligand (Figure 4c). One
common characteristic of multidrug-binding proteins is
their ﬂexibility to accommodate for different ligands in a
single ligand-binding pocket. This plasticity and ﬂexibility
can easily be seen in the Rv3066 regulator in which many
of these residues lining the binding site are found to par-
ticipate and relocate their side chain positions upon
ethidium binding.
To investigate if Rv3066 can accommodate different
drugs, we used the program AutoDock Vina (29) to
study how Rv3066 binds a variety of drugs. The docking
study shows that the large cavity of the multidrug-binding
site of each Rv3066 monomer can accommodate many
other drugs, such as acriﬂavine, proﬂavine, pyronin Y,



















































Figure 7. Representative ﬂuorescence polarization of Rv3066.
(a) The binding isotherm of Rv3066 with the 30-bp DNA containing
the IR1 sequence, showing a KD of 4.4±0.3 nM. (b) The binding
isotherm of Rv3066 with ethidium, showing a KD of 2.9±0.2 mM.
(c) The binding isotherm of Rv3066 with thioridazine, showing a
KD of 211.8±34.2mM. Fluorescence polarization is deﬁned by the
equation, FP=(VH)/(V+H), where FP equals polarization,
V equals the vertical component of the emitted light, and H equals
the horizontal component of the emitted light of a ﬂuorophore when
excited by vertical plane polarized light. FP is a dimensionless entity
and is not dependent on the intensity of the emitted light or on the
concentration of the ﬂuorophore. mP is related to FP, where 1 mP
equals one thousandth of a FP.
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drug was completely buried in the Rv3066 molecule, and
strong interaction was observed between the bound drug
and the regulator (Table 5). The dockings suggested that
all these ligands are bound in the same multidrug-binding
site with a similar binding mode, suggesting that the
process of induction by these drugs is similar.
A distinguishing feature of multidrug-binding proteins
that bind cationic drugs is the presence of buried acidic
glutamates or aspartates in the ligand-binding pockets.
This was clearly demonstrated by the structures of the
QacR–ligand complexes (33). Indeed, a completely
buried negatively charged aspartate, which is essential
for cationic ligand recognition, has also been found in
the ligand-binding pocket of the AcrR multidrug efﬂux
regulator (39). A similar characteristic for the TetR-
family regulators that recognize negatively charged
antimicrobials has also been observed through x-ray crys-
tallography (38,44). In this case, positively charged histi-
dines or lysines within the ligand-binding pockets are
critical for interacting with the negatively charged drugs.
For Rv3066, it is found that there is one negatively
charged residue (D156) inside the multidrug-binding
pocket. D156 is critical for ethidium binding as shown
using ﬂuorescence polarization and mutagenesis studies,
although this residue does not seem to contribute a sig-
niﬁcant electrostatic interaction to the cationic ligand.
A mutation of D156 with an alanine drastically decreases
the Rv3066–ethidium-binding afﬁnity by 20-fold. Instead
of contributing hydrogen-bonded interaction to neutralize
the formal positive charge of the bound ethidium, the
D156 residue, together with N112, is responsible for
forming hydrogen bonds with the aromatic residues,
Y101, Y115 and W131 (Figure 4b). These three residues,
in addition to W80, form an aromatic cage-like binding
pocket to position the bound ethidium (Supplementary
Figure S6), suggesting that D156 is important for the or-
ganization of the ligand-binding site. The importance of
the cage-like arrangement of these aromatic residues to
bind ethidium is further demonstrated using mutagenesis
and ﬂuorescence polarization studies, in which the W80–
W131 double mutant has been found to bind ethidium 20
times weaker than the wild-type Rv3066.
It is found that the Rv3066 dimer binds two drug mol-
ecules, with each subunit of the regulator contributing to
bind one drug. Gel-ﬁltration experiment conﬁrmed that
the Rv3066–IR1 complex should be in the form of 1:1
dimeric Rv3066-to-DNA molar ratio. Real-time quantita-
tive RT–PCR analysis suggested that the mmr gene was
signiﬁcantly up-regulated by thioridazine induction. This
result is indeed in good agreement with a recent ﬁnding
that the treatment of thioridazine on M. tuberculosis
causes a profound increase in the expression of the Mmr
multidrug efﬂux pump (12). The structures of the Rv3066
regulator both in the absence and presence of bound
ethidium, together with the experimental data from
electrophoretic mobility shift, footprinting analysis,
qRT–PCR, mutagenesis, gel ﬁltration and ﬂuorescence
polarization, support the role of Rv3066 in regulating
the expression level of the multidrug efﬂux pump Mmr
in M. tuberculosis.
Figure 8. Representative gel-ﬁltration experiment. The experiment demonstrated that two Rv3066 molecules are bound to one 30-bp DNA con-
taining the IR1 operator. The y-axis values were deﬁned as: Kav= (VeV0)/(VTV0), where VT, Ve and V0 are the total column volume, elution
volume and void volume of the column, respectively. Standards used were: A, cytochrome C (Mr 12 400); B, carbonic anhydrase (Mr 29 000); C,
albumin bovine serum (Mr 66 000); D, alcohol dehydrogenase (Mr 150 000); and E, b-Amylase (Mr 200 000). The void volume was measured using
blue dextran (Mr 2 000 000).
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PROTEIN DATA BANK ACCESSION CODES
Coordinates and structural factors for the structures
of Rv3066 have been deposited at the RCSB Protein
Data Bank with accession codes 3T6N (Form I,
apo-Rv3066), 3V6G (Form II, apo-Rv3066) and 3V78
(Rv3066–ethidium).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Figures 1–10.
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